- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02079168
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
June 13, 2016 updated by: RXi Pharmaceuticals, Corp.
A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
Study Overview
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Cristobal, Dominican Republic
-
-
-
-
Florida
-
Miami, Florida, United States, 33137
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults, 21-55 years of age.
- Two keloids of approximately similar size and anatomical location on the earlobe, neck, or torso.
- Keloids to be excised must have been present for > 1 year.
Exclusion Criteria:
- Use of tobacco or nicotine-containing products
- Pregnant or lactating
- Post-menopausal or full hysterectomy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid.
Dosing to begin at the time of surgery.
|
|
Experimental: Cohort 2
Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid.
Dosing to begin two weeks after surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in the recurrence of a keloid after keloid excision
Time Frame: 6 months
|
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of RXI-109
Time Frame: 6 months
|
To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective excision of a keloid
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
March 3, 2014
First Submitted That Met QC Criteria
March 4, 2014
First Posted (Estimate)
March 5, 2014
Study Record Updates
Last Update Posted (Estimate)
June 14, 2016
Last Update Submitted That Met QC Criteria
June 13, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RXI-109-1401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keloid
-
CHA UniversityCompletedHypertrophic or Keloid ScarsKorea, Republic of
-
Queen Mary University of LondonWithdrawn
-
SolitonEmergent Clinical Consulting, LLCCompleted
-
Sensus HealthcareUnknownKeloid ScarUnited States
-
Sensus HealthcareUnknown
-
University of UlmCompleted
-
NYU Langone HealthCompleted
-
Northwestern UniversityCompleted
-
Our Lady of the Lake HospitalLouisiana State University Health Sciences Center in New OrleansCompletedPost-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of KeloidsKeloid | Keloid Scar Following SurgeryUnited States
-
Next Science TMJacksonville Center For Clinical ResearchWithdrawnKeloid Scar Following SurgeryUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States